- Trials with a EudraCT protocol (79)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
79 result(s) found for: Elevated alkaline phosphatase.
Displaying page 1 of 4.
EudraCT Number: 2006-002276-17 | Sponsor Protocol Number: ET-B-025-02 | Start Date*: 2006-08-24 | |||||||||||
Sponsor Name:Pharma Mar SA, Sociedad Unipersonal | |||||||||||||
Full Title: Phase II Study of Yondelis® in Men with Advanced Prostate Carcinoma Estudio fase II con Yondelis en hombres con cáncer de próstata avanzado | |||||||||||||
Medical condition: Advanced Prostate Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007406-11 | Sponsor Protocol Number: ENB-002-08 | Start Date*: 2009-02-25 | |||||||||||
Sponsor Name:Enobia Canada Limited Partnership | |||||||||||||
Full Title: A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of ENB-0040 (Enobia’s human recombinant tissue non-specific alkaline phosphatase fusion protein) in up to 6 Severely Aff... | |||||||||||||
Medical condition: Infantile Hypophosphatasia | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019850-42 | Sponsor Protocol Number: ENB-010-10 | Start Date*: 2011-03-04 | |||||||||||
Sponsor Name:Alexion Pharma GmbH | |||||||||||||
Full Title: An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase alfa (human recombinant tissue nonspecific alkaline phosphatase fusion protein) in Infants a... | |||||||||||||
Medical condition: Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the gene encoding the Tissue-nonspecific alkaline phosphatase isoenzyme. With deficiency of Tissue-... | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) IT (Completed) ES (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000178-24 | Sponsor Protocol Number: W2021.040 | Start Date*: 2023-10-20 |
Sponsor Name: | ||
Full Title: Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial. | ||
Medical condition: patients with secondary hyperparathyroidism after Roux-en-Y gastric bypass surgery (RYGB). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004599-23 | Sponsor Protocol Number: GSN000300 | Start Date*: 2017-08-10 | |||||||||||
Sponsor Name:Genkyotex SA | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and wit... | |||||||||||||
Medical condition: Primary Biliary Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) ES (Completed) GR (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001762-13 | Sponsor Protocol Number: 747-401 | Start Date*: 2018-08-01 |
Sponsor Name:Intercept Pharmaceuticals, Inc. | ||
Full Title: A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients with Primary Biliary Cholangitis and Moderate to Severe Hepa... | ||
Medical condition: Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) HU (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-005683-21 | Sponsor Protocol Number: ENM-EA-030 | Start Date*: 2012-10-09 |
Sponsor Name:Medizinische Universität Graz | ||
Full Title: Effects of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial | ||
Medical condition: Primary hyperparathyroidism | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001816-56 | Sponsor Protocol Number: HUM 05-064 | Start Date*: 2006-05-11 |
Sponsor Name:Rigshospitalet | ||
Full Title: Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)? | ||
Medical condition: sarcoidosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-005140-24 | Sponsor Protocol Number: ISIS 301012-CS19 | Start Date*: 2008-06-05 | |||||||||||
Sponsor Name:Isis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled STudy to Assess Safety and Efficacy of ISIS 301012 Administration in Statin Intolerant Subjects | |||||||||||||
Medical condition: Patients with hypercholesterolemia who are intolerant to statins | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023783-41 | Sponsor Protocol Number: E7080-G000-303 | Start Date*: 2011-07-05 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double- Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I- Refractory Differentiated Thyroid Cancer | |||||||||||||
Medical condition: 131I-refractory differentiated thyroid cancer (DTC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) DE (Completed) ES (Completed) PL (Completed) DK (Completed) AT (Completed) IT (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000935-27 | Sponsor Protocol Number: 0468H1-313-EU | Start Date*: 2005-06-15 |
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.Clinical Research & Development Department | ||
Full Title: A Randomized, Open-label, Comparative Evaluation of Conversion from Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipi... | ||
Medical condition: Liver allograft recipients under maintenance therapy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-000680-26 | Sponsor Protocol Number: Taurine05 | Start Date*: 2005-06-27 |
Sponsor Name:North west London Hospital Trust | ||
Full Title: A randomised double blind controlled crossover trial of intravenous taurine supplementation in parenteral nutrition as an effective treatment for reducing hepatobiliary complications in chronic int... | ||
Medical condition: Complications of intravenous nutrition include cholestatic liver disease. This is one of the main causes of death during long-term home parenteral nutrition (HPN) and a study in 2000 found that 65%... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003648-70 | Sponsor Protocol Number: ML 19365 | Start Date*: 2007-02-08 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 ... | ||
Medical condition: First time treatment in chronic hepatitis C-infection patients with elevated GGT-level without coinfections as HBV, HDV and HIV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2021-001810-13 | Sponsor Protocol Number: GSN000350 | Start Date*: 2021-12-11 | |||||||||||
Sponsor Name:Genkyotex Suisse SA | |||||||||||||
Full Title: TRANSFORM: A 52-week, Randomized, Placebo controlled, Double blind, Adaptive Phase 2b/3 Trial of Setanaxib with a 52 week Extension Phase in Patients with Primary Biliary Cholangitis (PBC) and Elev... | |||||||||||||
Medical condition: Primary Biliary Cholangitis (PBC) and Elevated Liver Stiffness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) PL (Completed) IT (Completed) GR (Completed) SE (Completed) CZ (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003245-29 | Sponsor Protocol Number: SA652013 | Start Date*: 2016-12-19 |
Sponsor Name:Amsterdam AMC, locatie AMC | ||
Full Title: Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after Roux-en-Y gastric bypass and Sleeve Gastrectomy | ||
Medical condition: Prevention of symptomatic gallstone disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001961-34 | Sponsor Protocol Number: RDG-1/PBC | Start Date*: 2021-02-02 | |||||||||||
Sponsor Name:Dr. Falk Pharma GmbH | |||||||||||||
Full Title: Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of RhuDex granules with placebo in the treatment of primary biliary cholangitis | |||||||||||||
Medical condition: Primary biliary cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) HU (Prematurely Ended) SK (Prematurely Ended) NL (Prematurely Ended) BE (Completed) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004807-11 | Sponsor Protocol Number: BA058-05-021 | Start Date*: 2020-04-27 | |||||||||||
Sponsor Name:Radius Health Inc. | |||||||||||||
Full Title: A Randomized, Non-Inferiority, Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women with Osteoporosis | |||||||||||||
Medical condition: Osteoporosis in postmenopausal women | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) DK (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001015-23 | Sponsor Protocol Number: APHP180668 | Start Date*: 2020-05-13 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxyc... | ||
Medical condition: Adult patients with primary sclerosing cholangitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023124-24 | Sponsor Protocol Number: LUMCCHIP | Start Date*: 2011-03-02 | |||||||||||
Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum | |||||||||||||
Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ... | |||||||||||||
Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003934-32 | Sponsor Protocol Number: ISIS 301012-CS3 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Isis Pharmaceuticals Inc. | |||||||||||||
Full Title: A Phase II, Randomized, Double Blind, Placebo-Controlled Study to assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Varying Loading and Maintenance Dosing Regimens of ISIS 3... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
